C-reactive protein and family history of myocardial infarction

1999 ◽  
Vol 144 ◽  
pp. 17
Author(s):  
M. Margaglione ◽  
G. Cappucci ◽  
D. Colaizzo ◽  
G. Vecchione ◽  
E. Grandone ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Family History ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
History Of

Genetic Polymorphism of 5,10-MTHFR Reductase Gene in Offspring of Patients with Myocardial Infarction

1999 ◽  
Vol 82 (07) ◽  
pp. 19-23 ◽  
Author(s):  
Donatella Colaizzo ◽  
Giuseppe Cappucci ◽  
Annamaria del Popolo ◽  
Gennaro Vecchione ◽  
Elvira Grandone ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Family History ◽  
Plasminogen Activator Inhibitor ◽  
Mthfr Gene ◽  
C Reactive Protein ◽  
Plasminogen Activator Inhibitor 1 ◽  
Protein Levels ◽  
Reactive Protein ◽  
History Of ◽  
Activator Inhibitor

SummaryA family history of myocardial infarction is a major determinant of ischemic disease. A C->T677 polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene has been identified as a cause of mild hyperhomocysteinemia, a risk factor for arterial thrombosis. We have investigated the relationship between the MTHFR TT genotype and a family history of myocardial infarction in a cohort of 982 apparently healthy individuals. Subjects whose first-degree relatives suffered from a myocardial infarction, showed raised median age (p <0.001), total cholesterol (p <0.001) and plasma fibrinogen (p = 0.023) and a higher than normal frequency of C-reactive protein levels >0.33 mg/dl (p = 0.012). Moreover, when compared to subjects without such family history, a higher number of homozygotes for the T allele of the MTHFR gene (p = 0.027), and of the 4G allele of the plasminogen activator inhibitor-1 gene (p = 0.002) was found in the subsetting of the offspring of patients with myocardial infarction. In a multiple logistic regression analysis, age (OR 1.02 [95%-CI: 1.00-1.05]), total cholesterol (OR 1.40 [95%-CI: 1.14-1.71]), C-reactive protein levels >0.33 mg/l (OR: 1.87 [95%-CI: 1.10-3.20]), plasminogen activator inhibitor-1 4G/4G (OR: 1.84 [95%-CI: 1.27-2.66]), and MTHFR TT genotype (OR 1.62 [95%-CI: 1.08-2.42]), were all associated with a family history of myocardial infarction. Thus, the MTHFR TT genotype independently accounts for the risk of a family history for myocardial infarction in the present setting.

scholarly journals Association of Testosterone, Insulin-Like Growth Factor-I, and C-Reactive Protein with Metabolic Syndrome in Chinese Middle-Aged Men with a Family History of Type 2 Diabetes

2005 ◽  
Vol 90 (12) ◽  
pp. 6418-6423 ◽  
Author(s):  
Peter C. Y. Tong ◽  
Chung-Shun Ho ◽  
Vincent T. F. Yeung ◽  
Maggie C. Y. Ng ◽  
Wing-Yee So ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Family History ◽  
Total Testosterone ◽  
C Reactive Protein ◽  
Middle Aged ◽  
Reactive Protein ◽  
Igf I ◽  
History Of ◽  
Hs Crp

Context: Age-related declines in testosterone and IGF-I are associated with deposition of visceral fat, a component of the metabolic syndrome (MES). Objective: Testosterone and IGF-I may interact with familial disposition to diabetes mellitus to increase the association with MES. Design: We conducted a cross-sectional cohort study. Setting: The study was conducted in a university teaching hospital. Subjects: Study subjects included 179 middle-aged men with a family history of diabetes (FH) (aged 39.1 ± 8.1 yr) and 128 men without FH (aged 43.8 ± 8.5 yr). Main Outcome Measures: Clinical characteristics, frequency of MES using the World Health Organization criteria with Asian definitions of obesity (body mass index ≥ 25 kg/m2), and serum levels of total testosterone, IGF-I, and high-sensitive C-reactive protein (hs-CRP) were measured. Results: Men with FH had higher frequency of MES than those without FH [39.1 vs. 23.4% (P = 0.004)]. On multivariate analysis, smoking (former and current smokers), low total testosterone, and IGF-I but elevated hs-CRP levels explained 35% of the MES variance in men with FH. The frequency of MES increased with declining tertiles of total testosterone and IGF-I but increasing tertiles of hs-CRP. After adjustment for age and smoking history, subjects with all three risk factors had a 13-fold increase in risk association with MES compared with those without hormonal and inflammatory risk factors. These risk associations were not found in men without FH in whom only smoking (ex and current) and low total testosterone level were independent predictors for MES, which explained 14% of the variance. Conclusions: Clustering of FH, hormonal abnormalities, and high hs-CRP is associated with MES in Chinese middle-aged men.

Abstract 067: Predictors of High-sensitivity C-reactive Protein Elevation Among Patients With Myocardial Infarction: Insights From VIRGO and TRIUMPH

2017 ◽  
Vol 10 (suppl_3) ◽  
Author(s):  
Mohammed Qintar ◽  
Puza P Sharma ◽  
Yuanyuan Tang ◽  
Philip Jones ◽  
Yashashwi Pokharel ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
High Sensitivity ◽  
Peripheral Vascular ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
History Of ◽  
Multivariable Regression ◽  
Hs Crp

Background: Elevated hs-CRP is associated with worse cardiovascular outcomes in patients with acute myocardial infarction (AMI), but little is known about predictors of elevated hs-CRP after AMI. Methods: TRIUMPH and VIRGO are prospective AMI registries that assessed hs-CRP levels 30 days after AMI. TRIUMPH assessed hs-CRP levels at 6 months. Multivariable regression analysis was conducted to examine predictors of elevated hs-CRP [≥2.0 mg/L] at 30 days and at 6 months after an AMI (TRIUMPH only). Results: Of 3410 patients in both registries, 58.6% had elevated hs-CRP 30 days post AMI. Patients with elevated hs-CRP were more likely to be female, black, obese, smokers, to have had higher LDL-C at the time of their AMI, with more peripheral vascular disease and history of heart failure, and were less likely to have had a prior PCI (Table). In TRIUMPH, baseline hs-CRP ≥2 mg/L (n=1301) was significantly associated with elevated hs-CRP at 6 months (p<0.001). Patients with elevated hs-CRP at 6 months (n=407) were more likely to be black, obese, smokers, have peripheral vascular disease and have higher baseline hs-CRP. Conclusions: hs-CRP remains elevated in a large proportion of patients following AMI. We identified several predictors of elevated hs-CRP at 1 and 6 months post AMI. Further studies are needed to validate the findings and understand the utility of routine screening of hs-CRP in post AMI patients.

History of previous bleeding and C-reactive protein improve assessment of bleeding risk in elderly patients (≥80 years) with myocardial infarction

2015 ◽  
Vol 114 (11) ◽  
pp. 1085-1091 ◽  
Author(s):  
Lorenz Koller ◽  
David-Jonas Rothgerber ◽  
Patrick Sulzgruber ◽  
Feras El-Hamid ◽  
Stefan Forster ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Elderly Patients ◽  
Risk Score ◽  
Major Bleeding ◽  
Roc Analysis ◽  
Bleeding Risk ◽  
C Reactive Protein ◽  
Bleeding Events ◽  
Reactive Protein ◽  
History Of

SummaryWe aimed to assess whether the CRUSADE risk score represents a robust instrument for stratification of bleeding risk in elderly myocardial infarction (MI) patients (≥80 years) and further aimed to identify age-specific predictors of major bleeding events. Binary logistic regression models were applied to assess the effect of variables on the occurrence of bleeding events during hospital stay. Receiver operating characteristic (ROC) analysis was used to evaluate the discriminatory power. Out of 387 patients in the final study cohort, 74 patients (19.1 %) experienced a major bleeding event according to the definition of the International Society on Thrombosis and Haemostasis. The CRUSADE risk score demonstrated only a weak discriminatory power to predict bleeding in this group of patients (area under the ROC curve: 0.57 [0.51–0.65]; p=0.05). In the multivariate regression analysis, history of bleeding with an adjusted hazard ratio (HR) of 3.21(95 % confidence interval: 1.29–8.03, p=0.01) and C-reactive protein with an adjusted HR per increase of 10 mg/l of 1.05 (1.01–1.10) were independent predictors of major bleeding. Integration of both variables into the CRUSADE score demonstrated a significantly improved performance for bleeding as indicated by a significant increase in the ROC analysis (area under the curve: 0.64 vs 0.57; for comparison p<0.045), net reclassification index (35.6 0 %; p=0.006) and integrated discrimination increment (0.0242; p=0.02). In conclusion, bleeding history and C-reactive protein significantly improve the modest predictive power of the CRUSADE risk score in elderly patients with MI. These results point towards a specific risk profile for bleeding events in this high-risk group of patients.

scholarly journals Complement C3 and C-Reactive Protein Are Elevated in South Asians Independent of a Family History of Stroke

Stroke ◽  
2006 ◽  
Vol 37 (8) ◽  
pp. 2001-2006 ◽  
Author(s):  
Riyaz Somani ◽  
Peter J. Grant ◽  
Kirti Kain ◽  
Andrew J. Catto ◽  
Angela M. Carter
Keyword(s):  
Family History ◽  
South Asians ◽  
Complement C3 ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
History Of

scholarly journals Clinical and anamnestic characteristics of patients with non-ST elevation myocardial infarction after COVID-19

2021 ◽  
Vol 20 (7) ◽  
pp. 3062
Author(s):  
M. G. Chashchin ◽  
A. Yu. Gorshkov ◽  
O. M. Drapkina ◽  
I. V. Kositsyna ◽  
A. V. Golubev ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Troponin I ◽  
St Elevation Myocardial Infarction ◽  
Control Group ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Exertional Angina ◽  
History Of ◽  
St Elevation ◽  
Experimental Group

Aim. To study clinical, medical history and paraclinical characteristics of patients with non-ST elevation myocardial infarction (NSTEMI) after coronavirus disease 2019 (COVID-19).Material and methods. The study included 209 patients with NSTEMI who were admitted to the Demikhov City Clinical Hospital (Moscow). The patients were divided into 2 groups: the experimental one (n=104)  — those after COVID-19, the control one (n=105)  — those without history of COVID-19. All patients underwent routine diagnostic investigations in accordance with current standards and clinical guidelines.Results. The mean age of patients in the experimental group was 61,8±12,2 years, while in the control one — 69,0±13,0 years (p<0,0001). Myocardial infarction developed 49 days [34.0; 82.0] after COVID-19. Prior exertional angina was observed in 76,9% of patients in the experimental group and in 88,6% in the control one (χ2 =4,97; p=0,0258). The level of C-reactive protein in the experimental group was 19,2 mg/l [4,9; 53,0], and in the control one — 5,6 mg/l [0,4; 21,8] (p=0,0007). The average troponin I level in the experimental group was 2,7 ng/ml [1,3; 8,0], while in the control one — 1,8 ng/ml [0,8; 3,5] (p=0,0091).Conclusion. Patients with NSTEMI after COVID-19 were significantly younger compared to patients without a history of COVID-19. They had less common exertional angina prior to MI, while C-reactive protein and troponin I levels were significantly higher than in the control group. In addition, in NSTEMI patients after COVID-19, the estimated pulmonary artery systolic pressure was significantly higher compared to patients without a history of COVID-19.

Sign in / Sign up

Export Citation Format

Share Document